[Form 4] BIO-TECHNE Corp Insider Trading Activity
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Crouse Steven C. reported acquisition or exercise transactions in this Form 4 filing.
BIO-TECHNE Corp executive Steven C. Crouse reported new equity awards. On March 2, 2026, he received grants of 2,387 Performance Restricted Stock Units, 735 Restricted Stock Units, and 1,911 stock options, all held directly. Each restricted stock unit represents a contingent right to receive one share of BIO-TECHNE common stock, with various vesting dates extending through 2029 tied to service and, for the performance units, achievement of specified goals.
Positive
- None.
Negative
- None.
Insider Trade Summary
17 transactions reported
Mixed
17 txns
Insider
Crouse Steven C.
Role
President - Diag & Spatial Bi
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Performance Restricted Stock Units | 2,387 | $0.00 | -- |
| Grant/Award | Restricted Stock Units | 735 | $0.00 | -- |
| Grant/Award | Stock Option (right to buy) | 1,911 | $0.00 | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Performance Restricted Stock Units — 2,387 shares (Direct);
Restricted Stock Units — 735 shares (Direct);
Stock Option (right to buy) — 1,911 shares (Direct);
Common Stock — 5,894 shares (Direct)
Footnotes (1)
- Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. 794 restricted stock units vest on 5/1/2026 and 5/1/2027. 600 restricted stock units vest on each of 6/2/2026, 6/2/2027 and 6/2/2028. 1,379 restricted stock units vest on 8/15/2026. 1,868 restricted stock units vest on 8/15/2026 and 1,869 restricted stock units vest on 8/15/2027. 2,176 restricted stock units vest on each of 8/15/2026 and 8/15/2028; and 2,177 restricted stock units vest on 8/15/2027. 100% vested. Options to purchase 6,140 shares vest on each of 8/15/2023, 8/15/2024, 8/15/2025 and 8/15/2026. Options to purchase 3,162 shares vest on each of 8/15/2024, 8/15/2026 and 8/15/2027; and options to purchase 3,163 shares vest on 8/15/2025. Options to purchase 1,832 shares vest on each of 5/1/2025, 5/1/2026 and 5/1/2028; and options to purchase 1,831 shares vest on 5/1/2027. Options to purchase 4,283 shares vest on each of 8/15/2025, 8/15/2027 and 8/15/2028; and options to purchase 4,284 shares vest on 8/15/2026. Options to purchase 1,359 shares vest on each of 6/2/2026 and 6/2/2028; and options to purchase 1,358 shares vest on each of 6/2/2027 and 6/2/2029. Options to purchase 4,788 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2029; and options to purchase 4,787 shares vest on 8/15/2028. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). 245 restricted stock units vest on 3/2/2027, 3/2/2028 and 3/2/2029. Options to purchase 478 shares vest on each of 3/2/2027, 3/2/2028 and 3/2/2030; and options to purchase 477 shares vest on 3/2/2029.
